A retrospective analysis was conducted on three patients with primary myelofibrosis who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital from 2020 to 2023. They subsequently developed poor graft function. The patients received selected donor CD34(+) cell boosts as salvage therapy. There were two male patients and one female patient, with a median age of 68 (39-69) years. The median time from allo-HSCT to the selected donor CD34(+) cell boost was 83 (56-154) days. The median infusion of selected donor CD34(+) cells was 7.67 (7.61-9.06) ×10(6)/kg, with a CD34(+) cell purity of 97.76% (96.50%-97.91%) and a recovery rate of 70% (42%-75%) . Hematological recovery was achieved in two cases. No acute GVHD was observed in any of the three patients. One case of moderate oral chronic GVHD was noted. Selected donor CD34(+) cell boosts for the treatment of poor graft function after allo-HSCT in primary myelofibrosis was effective and no severe acute or chronic GVHD was observed.
回顾性分析上海市闸新中西医结合医院2020年至2023年行异基因造血干细胞移植（allo-HSCT）后发生移植物功能不良并接受供者CD34(+)细胞纯化输注挽救治疗的3例原发性骨髓纤维化患者，其中男2例，女1例，中位年龄68（39~69）岁。启动供者CD34(+)细胞纯化输注距allo-HSCT的中位时间为83（56~154）d。输注的纯化供者CD34(+)细胞中位数7.67（7.61~9.06）×10(6)/kg，CD34(+)细胞纯度97.76%（96.50%~97.91%），回收率70%（42%~75%），2例获得血液学恢复。3例患者均未观察到急性GVHD，1例发生口腔慢性GVHD（中度）。供者CD34(+)细胞纯化输注治疗原发性骨髓纤维化allo-HSCT后移植物功能不良有效且未观察到严重的急慢性GVHD。.